Posted by Michael Wonder on 04 Feb 2020
Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine
4 February 2020 - NICE has today published the outcome of the appeal against its final draft guidance on erenumab (Aimovig; Novartis) for preventing chronic migraine.
The independent appeal panel upheld one appeal point: the committee unreasonably failed to consider the cost-effectiveness of erenumab versus best supportive care in people with chronic migraine who had failed to benefit from the comparator drug (botulinum toxin) or when it is contra-indicated.
The appraisal committee has now been asked to request any available data to enable it to consider the role of erenumab when it is used at this point in the treatment pathway.
